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function in cancer because neutrophils
were shown to possess both pro- and
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subpopulations with conflicting cancer-
related properties. With tumor
progression, dynamic changes in
neutrophil composition result in a switch
from an overall anti- to protumor
neutrophil contribution.
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Controversy surrounds neutrophil function in cancer
because neutrophils were shown to provide both
pro- and antitumor functions. We identified a hetero-
geneous subset of low-density neutrophils (LDNs)
that appear transiently in self-resolving inflammation
but accumulate continuously with cancer progres-
sion. LDNs display impaired neutrophil function and
immunosuppressive properties, characteristics that
are in stark contrast to those of mature, high-density
neutrophils (HDNs). LDNs consist of both immature
myeloid-derived suppressor cells (MDSCs) and
mature cells that are derived from HDNs in a TGF-
b-dependent mechanism. Our findings identify three
distinct populations of circulating neutrophils and
challenge the concept that mature neutrophils have
limited plasticity. Furthermore, our findings provide
a mechanistic explanation to mitigate the contro-
versy surrounding neutrophil function in cancer.INTRODUCTION
Neutrophils are the predominant circulating leukocyte popula-
tion in humans, accounting for 50%–70% of circulating leuko-
cytes (Welch et al., 1989). Neutrophils play a well-established
role in host defense, where they phagocytose and kill invading
microorganisms by releasing activating cytokines, defensins,
and reactive oxygen species (Heifets, 1982; Mayadas et al.,
2014). In recent years, interest in these cells in the context of
cancer has increased because accumulating data suggest
important and significant roles for neutrophils in tumor biology
(Mantovani et al., 2011; Piccard et al., 2012).
The nonmalignant stroma surrounding the tumor plays a
crucial role in tumor initiation, growth, and metastatic progres-
sion. The function of cells in the tumor surroundings is modified562 Cell Reports 10, 562–573, February 3, 2015 ª2015 The Authorsby the growing tumor to generate a supportive microenviron-
ment (Joyce and Pollard, 2009). During the last years, the notion
that neutrophils are terminally differentiated cells with effects
limited to antimicrobial protection and inflammation is being
gradually revised. Recent evidence questions this limited point
of view, indicating that neutrophils can substantially affect tumor
growth (Galdiero et al., 2013; Galli et al., 2011). Several studies
have provided compelling evidence for protumor neutrophil
functions (Pekarek et al., 1995), and they were shown to promote
tumor angiogenesis, (Nozawa et al., 2006), enhance tumor cell
dissemination (De Larco et al., 2004), and to promote metastatic
seeding of tumor cells in distant organs (Kowanetz et al., 2010).
In contrast, other studies, including our own, have provided ev-
idence for antitumor and antimetastatic neutrophil functions.
Neutrophils were shown to limit malignant progression through
direct tumor cytotoxicity (Colombo et al., 1992; Hicks et al.,
2006) and enhancement of antitumoral mediators (Di Carlo
et al., 2001). It has also been demonstrated that neutrophils
can acquire a cytotoxic phenotype, accumulate in the premeta-
static organ and limit metastatic seeding (Granot et al., 2011; Lo´-
pez-Lago et al., 2013). Our understanding of neutrophil function
in human cancers is even more vague. Many patients with
advanced cancer show high levels of blood neutrophils (Schmidt
et al., 2005). The mechanisms by which tumors induce neutro-
philia are not fully understood, although granulocyte macro-
phage colony-stimulating factor production has been implicated
in several tumor types (McGary et al., 1995). Interestingly, neu-
trophilia and high neutrophil to lymphocyte ratio were found to
be associated with poorer prognosis inmany cancers (Fridlender
and Albelda, 2012).
These conflicting reports fuel a debate regarding the role
neutrophils play in cancer and bring forth the hypothesis that
neutrophil function may be dictated in a context-dependent
fashion. We were able to demonstrate that this is in fact the
case at the primary tumor microenvironment where transform-
ing growth factor-b (TGF-b) induces an N2 protumor neutrophil
phenotype, rather than the N1 antitumor phenotype (Fridlender
et al., 2009).
In the current work, we further explore the functional and
phenotypic plasticity neutrophils display in cancer, and in self-
resolving inflammation. We discovered and characterized a
distinct low-density neutrophil (LDN) subpopulation that appears
transiently in self-resolving inflammation and accumulates in tu-
mor-bearing mice and cancer patients. This LDN subpopulation
consists of at least two morphologically distinct neutrophil sub-
sets that are regulated via discrete mechanisms. We further
show that the mature, ‘‘normal,’’ high-density neutrophils
(HDNs) are capable of switching to become LDNs in a TGF-
b-dependent fashion, a switch accompanied by loss of anti-
tumor properties and the gain of immunosuppressive properties,
similar to what has been described for immature granulocytic
myeloid-derived suppressor cells (G-MDSCs) (Waight et al.,
2011; Youn et al., 2008). With this, the overall circulating neutro-
phil phenotype switches from mostly antitumor early on to
becomemore protumor with tumor progression. Taken together,
our data reveal the existence of neutrophil subpopulations with
conflicting functions and provides evidence for functional and
physical neutrophil plasticity. These insights offer a mechanistic
explanation tomitigate the controversy that surrounds neutrophil
function in cancer and highlight unexplored aspects of neutrophil
biology.
RESULTS
Distinct Circulating Neutrophil Subpopulations in
Cancer
Neutrophils’ contribution to tumor growth and metastatic pro-
gression has been a matter of debate where compelling evi-
dence show both pro- and antitumor functions. This has led us
to speculate that rather than being a homogenous population,
circulating neutrophils consist of several subpopulations whose
function in the context of cancer might differ considerably. To
test this hypothesis, we used the 4T1 mouse mammary tumor
model where circulating neutrophil numbers continuously
increased with tumor progression (Figure 1A). When purifying
neutrophils on a density gradient, we noticed that a significant
proportion of neutrophils copurifies with the low-density (LD)
mononuclear cells layer (Figure 1B, M) rather than the expected
high-density (HD) granulocytic fraction (Figure 1B, G). In tumor-
free mice (Figures 1C and 1D), over 95% of the neutrophils
were high-density neutrophils (HDNs). However, with tumor
progression the proportion of low-density neutrophils (LDNs)
increased dramatically to the extent that LDNs often became
the dominant circulating neutrophil population (Figure 1C). This
phenomenon was also seen in other mouse models of breast
cancer (E0771 and AT-3), mesothelioma (AB12), and orthotopic
K-ras-driven lung cancer (K-ras) (Figure 1D). Interestingly,
whereas increase in LDN prevalence was greater than 5-fold in
all models tested (Figure 1E), there was significant variability in
the extent of LDN propagation between different models. We
noted that propagation of LDNs correlates well with the extent
of neutrophil mobilization (data not shown); however, HDNs are
still abundant in the bone marrow when LDNs are deployed,
suggesting that LDN release from the bone marrow may not be
due to the mere depletion of HDNs (Figure S1). Furthermore,
LDNs had higher forward scatter (FSC) than HDNs with similarCside scatter (SSC) (Figure 1F), suggesting that they are larger
than HDNs while maintaining similar granularity. Interestingly,
LDNs had reduced CD11b expression, which may indicate a
lower state of activation (Borregaard et al., 1994) (Figure 1F).
We also found that a subset of LDNs (5%) had increased
expression of TRAIL (Figure S2) raising the possibility that this
LDN subpopulation may play a role in antitumor immunity (Cret-
ney et al., 2002). Extensive fluorescence-activated cell sorting
(FACS) analyses showed no other significant differences be-
tween HDNs and LDNs in commonly used neutrophils-related
surface markers (Figure S2). In addition, morphological analyses
showed that, whereas HDNs appeared to be a homogenous
population of mature, segmented neutrophils (Figure 1G),
LDNs were heterogeneous and contained segmented (35%)
as well as morphologically immature (banded and ring-shaped;
Tsuda et al., 2004; Zhu et al., 2007) neutrophils (Figures 1H
and 1I).
LDNs in Human Cancer Patients
Next, we wanted to test whether LDNs are also generated during
the natural course of the disease in cancer patients. Although
LDNs were rare in healthy volunteers (n = 9), their prevalence
in the LD fraction was significantly increased in cancer patients
(n = 15; Figures 2A and 2B). Furthermore, resembling the mouse
phenotype, LDNs had increased FSC and similar SSC in patients
(Figure 2C), but increased surface expression of CD11b (Fig-
ure 2D). In addition, human LDNs had increased surface ex-
pression of CD66b (Figure 2E), another marker of neutrophil
activation. The similarity between human and mouse HDNs
and LDNs was further manifested in their cellular composition
in patients; HDNs were a homogeneous population of mature
(segmented) neutrophils, whereas LDNs were heterogeneous
and consisted of both immature (banded) and mature neutro-
phils (Figure 2F). This finding was also observed by FACS ana-
lyses where two subpopulations distinct in size (FSC) were noted
within the LDNs (Figure 2C, left panel). Of note, there was no sig-
nificant difference in the age distribution between healthy volun-
teers (57.4 ± 4.6 years, range 38–87) and cancer patients (64.4 ±
2.5 years, range 40–79). Most patients had advanced disease
(stage IV), and we found no correlation between the tumor
type, tumor site, or treatment history and the extent of LDN prop-
agation (Table S1).
Taken together, the observations made in patients and in
mouse models of cancer suggest that LDNs consisting of both
mature and immature neutrophils are generated during the nat-
ural course of the disease.
LDNs Consist of Neutrophils Derived from Two Distinct
Cellular Origins
Because LDNs consist of both immature and mature cells, we
wanted to gain insight into their cellular origin. Do they represent
different stages of differentiation of the same cell or are they
distinct neutrophil subpopulations? To answer this question,
we performed a bromodeoxyuridine (BrdU) pulse-chase experi-
ment and followed the rate by which newly generated neutro-
phils populate the LD and HD fractions. Within 24 hr of BrdU
injection, the LDN fraction was populated by 50% BrdU+ cells,
whereas only3% of the HDNs were BrdU+ (Figure 3A). Overall,ell Reports 10, 562–573, February 3, 2015 ª2015 The Authors 563
Figure 1. Dynamic Changes in Neutrophil
Subpopulations with Cancer Progression
(A) Circulating CD11b+Ly6G+ neutrophil numbers
continuously increase with 4T1 tumor progression
in Balb/c mice.
(B) Separation of whole blood retrieved by cardiac
puncture on a Histopaque density separating
granulocytes (G), mononuclear cells (M), and
RBCs (R).
(C) The percentage of LDNs out of all
CD11b+Ly6G+ cells increases dramatically with
4T1 tumor progression in Balb/c mice.
(D) The proportion of LDNs (of total neutrophils)
increases dramatically in mice bearing E0771, AT-
3, AB12, and K-ras-driven orthotopic lung tumors
(all in red) compared to naive mice (white).
(E) Fold increase in LDN prevalence in the different
tumor models.
(F) FACS analysis showing similar SSC but
increased FSC in LDNs (red) compared to HDNs
(blue).
(G) Cytospin images of the HD fraction showing
that HDNs are a homogenous population of
segmented neutrophils.
(H) Cytospin images of the LD fraction showing
that LDNs are morphologically heterogeneous
consisting of immature neutrophils with ring-sha-
ped (1) and banded (2) nuclei as well as mature
segmented neutrophils (3).
(I) Ratio of immature (ring-shaped and banded) to
matureneutrophils in theHDNversusLDNfractions.
Error bars represent ±SEM. **p < 0.01.
See also Figures S1 and S2.95% of newly generated Ly6G+ cells at this time were found in
the LDN fraction, whereas only 5% were found to be HDNs (Fig-
ure 3B). By 48 hr, the situation changed dramatically where
50% of the HDNs were BrdU+ (Figure 3A), down to 30% at
72 hr. These results suggest that immature CD11b+Ly6G+ cells,
possibly G-MDSCs, rapidly leave the bone marrow. An addi-
tional day is required to reach full maturation from dividing
precursor cells, and only by then the HDN layer is populated.
Interestingly, the BrdU+Ly6G+ population in the HD fraction in-564 Cell Reports 10, 562–573, February 3, 2015 ª2015 The Authorscreases dramatically from 24 to 48 hr
postlabeling; however, the proportion of
BrdU+ LDNs does not change much dur-
ing this time (Figure 3A). The different dy-
namics of LDNs and HDNs may be better
illustrated by presenting the distribution
of BrdU+Ly6G+ cells between these frac-
tions, where 95% of BrdU+Ly6G+ cells
are LDN after 24 hr, whereas 70% of
the labeled cells are HDNs after 72 hr
(Figure 3B). Importantly, the HDN/LDN
ratio remains similar throughout the ex-
periment (Figure 3C), suggesting that,
although there are significant dynamic
changes in the composition of the neutro-
phil subpopulations, these changes do
not affect the HDN/LDN ratio, or the totalneutrophil number. In addition, at 48 hr there was still a signifi-
cant amount of BrdU labeling in bone marrow neutrophils (data
not shown) and a very low rate of apoptosis in freshly isolated
circulating HDNs and LDNs (Figure 3D).
These findings suggested that the LDN fraction may also be
populated by BrdULy6G+ cells coming from another source
and raised the striking possibility that LDNs are derived, at least
in part, from neutrophils in the HD fraction. To test this hypothe-
sis, we followed the fate of labeled HDNs and LDNs adoptively
Figure 2. Heterogeneous LDNs Are Also Found in Cancer Patients
(A) FACS analysis of the percentage of LDNs (CD66+ cells) out of the entire LD fraction in healthy volunteers (blue) and in cancer patients (red).
(B) FACS analysis of the percentage of LDNs out of the entire neutrophil (CD66+ cells) population in healthy volunteers (blue) and in cancer patients (red).
(C) FACS analysis of LDNs (red) and HDNs (blue) isolated from blood of a lung cancer patient showing that LDNs have increased FSC with no change in SSC.
(D and E) Patient LDNs show increased surface expression of CD11b (D) and CD66b (E) compared to HDNs.
(F) Cytospin images of the HD and LD fractions in a lung cancer showing homogeneous HDNs and heterogeneous LDNs, consisting of both segmented (blue
arrows) and banded neutrophils (red arrows), in the LD fraction.
Error bars represent ±SEM. **p < 0.01. See also Table S1.transferred into label-free tumor-bearing mice (Figure 3E). The
recipient mice were sacrificed 3 hr after neutrophil transfer and
their neutrophils were refractionated (Figure 3E). Using this strat-
egy, we found an impressive phenotypic switch:40% of trans-
ferred labeled HDNs shifted to the LD fraction and 10% of
transferred labeled LDNs shifted to the HD fraction (Figure 3F),
demonstrating the plasticity of these circulating neutrophils
in vivo.
LDNs Increase Transiently during Self-Resolving
Inflammation
A major question arising from our results was whether similar
transitions between HDN and LDN are relevant not only to the
persistent inflammation associated with cancer, but also to other
states of inflammation. To this end, we studied zymosan-induced
peritonitis, a widely used model for acute and self-resolving
inflammation that peaks within a few hours with an influx of neu-
trophils to the peritoneum and is mostly resolved by 72 hr (Ban-
nenberg et al., 2005). In this context of limited inflammation,
circulating and peritoneal LDNs increased transiently, peaking
at 48 hr (Figure 3G). With striking resemblance to the ob-
servations made in tumor-bearing mice, peritoneal HDNs are a
homogeneous population of mature neutrophils, whereas LDNs
consist of bothmature and immature neutrophils (Figure 3H) sug-
gesting that circulating LDNs are also associated with self-
resolving inflammation. Adoptive transfer experiments showed
that within 3 hr of their transfer into the peritoneum, 90% of
labeled HDNs switched to the LD fraction, whereas only 16%
of labeled LDNs switched to the HD fraction (Figure 3I). Impor-Ctantly, significant numbers of BrdU-labeled HDNs could be de-
tected in the circulation and peritoneum only 48 hr following
BrdU administration, suggesting that this represents the normal
timing of neutrophil maturation and release to the circulation
under inflammatory conditions (Figure 3J). Together, the obser-
vations made in tumor-bearing mice and in mice with acute
peritoneal inflammation suggest that BrdU+ HDNs cannot be
detected in the circulation earlier than 48 hr following BrdU
administration. This means that HDNs require 48 hr to fully
mature, supporting our hypothesis that the BrdU+ neutrophils
seen in the LD layer at 24 hr are indeed immature cells (Figure 3A).
During the resolution of inflammation peritoneal macrophages
undergo a conversion from a CD11bhigh to a CD11blow pheno-
type that is accompanied by an increase in the expression of
12-/15-lipoxygenase (LO) and a decrease in arginase-1 (Schif-
Zuck et al., 2011). Hence, we tested the consequences of intro-
ducing LDNs from 4T1 tumor-bearing mice into the peritoneum
of mice with zymosan-A-induced peritonitis. LDNs were trans-
ferred at 24 hr following zymosan induction, and the mice were
sacrificed at 48 hr. Our data show that LDN transfer induced a
switch in the WBC composition in the peritoneum and a reduc-
tion in the overall number of peritoneal WBC compared with
vehicle-treated controls (Figure S3). These changes were ac-
companied with a reduction in CD11b expression and an in-
crease in 12/15-LO and arginase-1.
Together, our findings in both cancer and inflammation sug-
gest the existence of at least three distinct neutrophil subpopu-
lations in the circulation classified into immature LDNs, mature
LDNs, and mature HDNs. The dynamic transition between theseell Reports 10, 562–573, February 3, 2015 ª2015 The Authors 565
Figure 3. The Origins and Plasticity of
Neutrophil Subpopulations
(A) The percentage of Ly6G+BrdU+ neutrophils in
the HD (blue) and LD (red) fractions as determined
at 24, 48, and 72 hr after BrdU labeling.
(B) Distribution of BrdU+ neutrophils between the
HD and LD fractions at 24, 48, and 72 hr after BrdU
labeling.
(C) HDN/LDN ratio does not change during the
time course of the experiment.
(D) FACS analysis of Annexin-V+ cells in freshly
isolated HDNs (blue) and LDNs (red) shows very
low levels of cells undergoing apoptosis.
(E) Labeled HDNs and LDNs were purified and
introduced via intracardiac injection to tumor-
bearing mice (LDN recipients and HDN recipients).
Three hours later, neutrophils were refractionated
and the distribution of labeled neutrophils in the
low- and high-density fractions was determined
by flow cytometry.
(F) Sixty percent of the labeled HDNs were de-
tected in the LD fraction, whereas 10% of the
labeled LDNs were detected in the HD fraction,
suggesting for dynamic transition between these
neutrophil subpopulations.
(G) Appearance of LDNs in the circulation (red) and
peritoneum (pink) in the zymosan-induced model
of peritonitis at 24, 48, and 72 hr after zymosan
administration.
(H) Cytospin imaging of peritoneal LD and HD
fractions taken at 48 hr after zymosan injection.
HDNs exclusively consist of mature neutrophils,
whereas LDNs consist of both mature (blue ar-
rows) and immature (red arrows) neutrophils.
(I) Approximately 70% of the labeled HDNs intro-
duced into the inflamed peritoneum (blue) switch
to the LD fraction (red), whereas 16% of the
labeled LDNs were detected in the HD fraction.
(J) Time course of BrdU+ HDN accumulation in the
circulation (blue) and peritoneum (light blue) in
zymosan-induced peritonitis.
Error bars represent ±SEM. See also Figure S3.subpopulations may account for the significant numbers of
mature neutrophils in the LD fraction (Figures 1G and 1H).
HDN to LDN Transition Occurs Spontaneously in
Late-Stage Tumor-Bearing Mice, Outweighs the
Opposite Transition, and Is Not Merely Degranulation
Although these findings highlight an aspect of neutrophil biology,
the low retrieval rate (5%) of adoptively transferred neutrophils
precludes a clear indication ofwhether the transition fromHDN to
LDN predominates, or vice versa. To overcome this difficulty, we
tested whether the transition between HDN and LDN can be
mimicked in confined conditions, ex vivo. We compared the
HDN/LDN ratio in freshly drawn blood and in whole blood incu-
bated for 4 hr ex vivo. Under these conditions, the rate of
apoptosis increases significantly with time in both HDNs and566 Cell Reports 10, 562–573, February 3, 2015 ª2015 The AuthorsLDNs. LDNs consistently had a reduced
rate of apoptosis compared with HDNs
(Figure 4A). That said, we were able to
retrieve close to 100% of neutrophilsfollowing 4 hr of incubation ex vivo. Although there was no
apparent change in the HDN/LDN ratio after incubation in blood
taken frommice bearing early tumors (Figure 4B, day 13 posten-
graftment), 90% of all neutrophils in blood taken from mice
bearing late tumors were located in the LD fraction after 3 hr of
incubation (Figure 4B, day 25 postengraftment). These results
corroborated the experiments made in vivo and show that the
HDN to LDN transition occurs spontaneously in blood from
late-stage tumor-bearing mice. Given the fact that we were
able to retrieve close to 100% of neutrophils, this result demon-
strates that the transition from HDN to LDN significantly out-
weighs the transition in the opposite direction. Transition is
evident only in blood drawn frommice bearing late-stage tumors,
suggesting that it may be mediated via a change in the cytokine/
chemokine milieu that is associated with advanced disease.
Figure 4. HDNs from Late-Stage Tumor-Bearing Mice Spontane-
ously Switch to LDNs In Vitro
(A) Extent of apoptosis (Annexin-V+) in purified HDNs (blue) or LDNs (red) at 2,
4, and 24 hr.
(B) The percentage of LDNs out of all Ly6G+ neutrophils in freshly drawn whole
blood (red) and in blood incubated ex vivo for 3 hr (green) inmice bearing early-
(day 13) and late- (day 25) stage tumors.
(C) Representative TEM images of segmented neutrophils taken from the HD
or LD fractions.
(D) The number of granules per cell (<20 per group) in HDNs (blue) and
segmented LDNs (red).
(E) Cell size measurements show that LDNs (red) are significantly larger than
HDNs (blue).
Error bars represent ±SEM.What regulates the transition from HDN to LDN? Neutrophils
have the capacity to respond to a wide range of stimuli. This
responsemay lead to changes in density as a result of a dramatic
decrease in cellular content (i.e., degranulation), a change in cell
volume (i.e., increase in size) or a combination of both processes
(Jan et al., 2006). To understand which of these processes me-
diates the change in neutrophil density, we used transmission
electron microscopy (TEM) focusing on segmented LDNs andCHDNs. This analysis showed that, whereas LDNs were indeed
larger than HDNs, both neutrophil subpopulations contained a
similar number of granules (Figures 4C–4E). This finding was in
line with the FACS analyses showing increased FSC with un-
changed SSC (Figures 1E and 2C) and suggests that, in this
context, LDNs are not derived from degranulated HDNs.
TGF-b Mediates the Transition from HDN to LDN
We have previously demonstrated that TGF-b has a dramatic ef-
fect on neutrophils function as it can efficiently block neutrophil
cytotoxicity (Granot et al., 2011) and mediate the polarization
of tumor-associated neutrophils from antitumor N1 neutrophils
to protumor N2 neutrophils (Fridlender et al., 2009). These obser-
vations were supported by the fact that TGF-b inhibited neutro-
phil H2O2 production in response to phorbol myristate acetate
(PMA), a pan-PKC receptor-independent neutrophil activator
(Figure 5A) and degranulation induced by lipopolysaccharide
(Shen et al., 2007). Because H2O2 was shown to mediate anti-
tumor neutrophil cytotoxicity (Granot et al., 2011) and PMA
was found to be sufficient for inducing antitumor neutrophil cyto-
toxicity (Ackermann et al., 1989), its inhibitory effect on PMA-
induced H2O2 secretion highlights TGF-b as a major regulator
of neutrophil cytotoxicity. Furthermore, the circulating levels of
TGF-b were shown to correlate with tumor progression (Barcel-
los-Hoff and Akhurst, 2009), making it a prime candidate for pro-
moting the transition from HDN to LDN. To examine if TGF-b is
sufficient for inducing the transition from HDN to LDN, we tested
whether incubating whole blood ex vivo in the presence of
increasing concentrations of TGF-b canmodify the LDN/HDN ra-
tio. Indeed, we observed a dose-dependent increase in the pro-
portion of LDNs with the addition of TGF-b (Figure 5B). We next
incubated GFP+ HDNs in whole blood taken from tumor-bearing
GFP mice, in the presence or absence of SB431542, an inhib-
itor of TGF-b signaling. We could therefore distinguish the donor
GFP+ HDNs from the unlabeled neutrophils present in the re-
cipient blood. SB431542 induced a moderate but significant
inhibition of HDN to LDN transition in the unlabeled neutrophil
population (Figure 5C). This effect of SB431542 was far more
pronounced when looking specifically at the GFP+ HDN popu-
lation where the transition from HDN to LDN was dramatically
inhibited (Figure 5D, left). Interestingly, GFP+ HDNs efficiently
switched to LDNs not only in blood taken from tumor-bearing
mice, but also in blood drawn from tumor-free mice. In contrast,
HDNs from tumor-free mice incubated in blood drawn from
either tumor-free or tumor-bearing mice did not show significant
transition to LDN (Figure 5D, right), demonstrating that the mere
transfer of HDNs from tumor-free mice to blood drawn from
tumor-bearing mice is not sufficient for inducing the HDN to
LDN transition. Moreover, it suggests that neutrophils in tumor-
bearing mice have undergone preconditioning that directs
them toward the transition to LDN even in blood from tumor-
free mice. To further provide insight into the role TGF-b plays
in regulating the LDN/HDN ratio in vivo, we treated tumor-
bearing mice with the TGF-b-depleting antibody 1D11. Adminis-
tration of 1D11 to tumor-bearing mice results in a reduced LDN/
HDN ratio (Figure 5E), suggesting that TGF-b is involved in regu-
lating this ratio in vivo. However, because TGF-b alone had no ef-
fect on the number of LDNs (Figure 5F) or the proportion LDNsell Reports 10, 562–573, February 3, 2015 ª2015 The Authors 567
Figure 5. TGF-b Signaling Is Both Required
and Sufficient for Driving the HDN to LDN
Transition in Tumor-Bearing Mice
(A) TGF-b is a potent inhibitor of H2O2 production
by PMA-stimulated neutrophils.
(B) Ex vivo incubation of whole blood from tumor-
bearing mice with increasing TGF-b concentra-
tions.
(C) Ex vivo incubation (3 hr) of whole blood drawn
from tumor-bearing mice with SB431542 (TGF-bi).
(D) HDNs purified from naive or tumor-bearing
GFP+ mice incubated ex vivo for 3 hr in whole
blood from GFP naive (Naive bl., green) or tumor-
bearing mice in the absence (Tumor bl., blue) or
presence of SB431542 (Tumor bl.+TGF-bi, red).
Data show the percentage of GFP+ LDNs make of
all GFP+ neutrophils.
(E) Administration of 1D11 to tumor-bearing mice
results in a significant reduction in the proportion of
LDNscomparedtovehicle-treatedcontrols (vehicle).
(F and G) Ex vivo incubation of whole blood from
naive mice with TGF-b (10 ng/ml) has no significant
effect on the number of LDNs (F) or the fraction
they make of the entire neutrophil population (G).
Error bars represent ±SEM.make of the entire neutrophil population (Figure 5G), we
conclude that, whereas TGF-b is required and sufficient for
driving the HDN to LDN transition in tumor-bearing animals,
naive neutrophils require further activation for this transition.
HDNs and LDNs Show Remarkably Opposing
Cancer-Related Functions
We evaluated several basic neutrophil functions and found that
LDNs show impaired activity compared to HDNs: (1) LDNs
showed reduced chemotaxis toward 4T1-conditioned media
compared with HDNs (Figures 6A and 6B); (2) LDNs were able
to phagocytose fewer FITC-labeled microbeads than did HDNs
(Figure 6C); and (3) LDNs had impaired oxidative burst,
compared with HDNs, in response to PMA (Figure 6D). The
reduced H2O2 release following PMA induction suggested that
under maximal stimulation, using this receptor-independent
activator, LDNs might have flawed antitumor activity compared
with HDNs. To test this hypothesis, we analyzed cancer-related
properties of these neutrophil subsets. Cancer-related HDNs,
previously referred to as tumor-entrained neutrophils (TENs)
(Granot et al., 2011), showed high cytotoxicity toward tumor cells
in culture (Figure 6E), whereas LDNs showed no significant cyto-
toxicity. We next tested whether the reduced LDN cytotoxicity
stems from the interaction with other LD suppressive cells. For
this purpose, we added a 1:1 mixture of HDNs and cells of the
LD fraction to the coculture and saw no significant difference
in cytotoxicity, suggesting that the cells in the LD mononuclear
fraction have no significant effect on the cytotoxic capacity of
HDNs (Figure 6F). Tumor cell killing by HDNs from mice with
early-stage tumors was similar to HDNs from late-stage tumors
(Figure 6G), showing that, although there is a dramatic increase
in LDNs with tumor progression, the generation of tumor-cyto-
toxic HDNs (TENs) persists.
We next performed a modified Winn assay to test the conse-
quences of coinjecting tumor cells with either HDNs or LDNs568 Cell Reports 10, 562–573, February 3, 2015 ª2015 The Authorson tumor growth. Although LDNs had no significant effect on
initial tumor growth, HDNs dramatically retarded tumor growth
(Figure 6H), demonstrating that HDNs play an antitumor role,
whereas LDNs are tumor permissive. Because several studies
have suggested a protumor role for neutrophils (De Larco
et al., 2004; Fridlender and Albelda, 2012; Kowanetz et al.,
2010; Nozawa et al., 2006; Pekarek et al., 1995; Piccard et al.,
2012), we hypothesized that LDNs may represent the protumor
neutrophil subset. We found that LDNs have a gene expression
signature associated with a reduced inflammatory state
including reduced expression of various chemokines (CXCL1,
CXCL2, CXCL10, CCL2, and CCL3), chemokine receptors
(CXCR2 and CCR5), and proinflammatory molecules, but with
increased expression of CCR7 (Figure S4), that is known to be
rapidly expressed at themembrane upon stimulation (Beauvillain
et al., 2011). Most importantly, LDNs spontaneously generated
from HDNs acquired a previously nonexisting suppressive ca-
pacity and markedly limited the proliferation of aCD3-stimulated
CD8+ T cells (Figures 6I–6J). This observation demonstrates the
striking extent of neutrophil plasticity and challenges the
concept that only immature myeloid cells contribute to immune
suppression in cancer. This effect was shown to have impact
in vivo, and, using another modification of the Winn assay, we
found that the inhibition of tumor growth induced by mixing
tumor cells with CD8+ cytotoxic T lymphocytes (CTLs) was
abrogated when LDNs were added to the mixture (Figure 6K).
Altogether, our data suggest the existence of three distinct circu-
lating neutrophil subpopulations in cancer, namely, HDNs that
possess antitumor functions and LDNs that possess protumor
functions and consist of MDSCs and mature neutrophils.
DISCUSSION
Neutrophils, the predominant circulating leukocyte population
(Welch et al., 1989), play a well-established role in host defense
Figure 6. HDNs and LDNs Differ in General and Cancer-Related Functions
(A) Reducedmigration of LDNs (red), purified from either 4T1 or AB12 tumor-bearing mice, compared to HDNs (blue). The number of migrating cells was counted.
(B) Representative images of light microscopy showing the extent of HDN versus LDN migration in a Boyden chamber (bottom well).
(C) LDNs (blue) have reduced phagocytic capacity of labeled beads compared with HDNs (red).
(D) LDNs (blue) show reduced PMA induced oxidative burst compared with HDNs (red).
(E) LDNs show reduced cytotoxicity toward tumor cells compared with HDNs (blue).
(F) Coculture of tumor cells with HDNs alone or together with LDN (1:1 ratio) shows that LDNs have no significant inhibitory effect on HDN cytotoxicity.
(G) HDNs purified from early- and late-stage tumors show similar cytotoxicity.
(H) HDNs (blue) but not LDNs (red) reduce tumor size compared with control (green) in a modified Winn assay.
(I and J) In vitro CD8+ T cell proliferation, asmeasured by reduction in carboxyfluorescein succinimidyl ester (CFSE) labeling assay. Stimulation with aCD3 induces
proliferation (aCD3, light blue) compared to nonstimulated (ns, green). HDNs (blue) have no impact on CD8+ T cell proliferation (aCD3+HDN), whereas LDNs (red)
significantly inhibit T cell proliferation (I). LDNs, but not HDNs, significantly reduce the number of CD8+ T cells in a splenocyte culture stimulated with aCD3 (J).
(K) LDNs (red) abrogate the tumor limiting effect of CD8+ CTLs (light blue) in a modified Winn assay. Control mice were injected with tumor cells alone (green).
Error bars represent ±SEM. See also Figure S6.(Heifets, 1982; Mayadas et al., 2014). Interest in these cells in
the context of cancer has increased during the last decade,
because accumulating data suggest important and significant
roles for neutrophils in tumor biology (Mantovani et al., 2011;
Piccard et al., 2012). Controversy, however, surrounds the
role these cells play in tumor growth and metastatic progres-
sion. Neutrophils have been shown to contribute to tumor pro-
gression by secreting chemokines, cytokines, growth factors,
and ECM remodeling enzymes and through promotion of angio-
genesis and metastatic seeding. In addition, neutrophils may
play an important part in mediating tumor immune evasion
both as immature neutrophils (G-MDSCs) (Peranzoni et al.,
2010) and as mature cells (e.g., by attracting T-regulatory cellsCto the tumor bed, recently reviewed in Sionov et al., 2014).
In contrast, other reports have shown that neutrophils also
possess antitumor properties where they acquire the capacity
to kill tumor cells either directly or through antibody-dependent
cellular cytotoxicity (ADCC) (Kushner and Cheung, 1992) and
limit tumor growth and metastatic seeding (Granot et al.,
2011; Lo´pez-Lago et al., 2013).
Dynamic Changes in Neutrophil Subpopulations with
Tumor Progression
In our current work, we show that circulating neutrophils,
both in cancer patients and in mouse models of cancer, are
heterogeneous and consist of distinct subpopulations. Theseell Reports 10, 562–573, February 3, 2015 ª2015 The Authors 569
subpopulations are dynamic, have distinct cellular origins, and
may possess different and even conflicting functions in the
context of cancer. The ratio between these subpopulations
and the potency of their activity should determine the overall ef-
fects of neutrophils. This notion is supported by our previous
studies showing that within the tumor microenvironment, neu-
trophils acquire a tumor-promoting ‘‘N2’’ phenotype in a TGF-
b-dependent manner (Fridlender et al., 2009). We further
show that subpopulations of circulating neutrophils in cancer
can be distinguished according to their densities, one with
‘‘normal,’’ HD characteristics (HDNs) having antitumor proper-
ties (Figures 1 and 2), which we have previously described as
TENs (Granot et al., 2011), whereas the other (LDNs) being of
lower density with features associated with protumor activity.
The functional differences between HDNs and LDNs together
with the continuous increase in the proportion of LDNs with tu-
mor progression provide a solid explanation for the controversy
that has surrounded neutrophil function in cancer. Namely, the
ratio between the functionally opposing neutrophil subtypes
dictates the overall pro- or antitumor contribution of neutro-
phils. During early tumor development, HDNs predominate
leading to an overall antitumor response. With tumor progres-
sion, LDNs become dominant resulting in an overall neutrophil
phenotype switch toward tumor-permissive functions. These
results mirror our previous findings that tumor neutrophils enter
the tumor and become more protumor with tumor progression
(Mishalian et al., 2013). Importantly, because our data show
that significant expansion of LDNs is a relatively late event,
we propose that, whereas LDNs may contribute to tumor
growth and progression, their contribution to tumor initiation
is less likely.
Generation of LDNs in Cancer: A Futile Attempt at
Resolving Tumor-Associated Inflammation?
Our findings raise a major question regarding the biological sig-
nificance of the large numbers of LDNs in cancer. A possible
explanation may be deduced from the observation that LDNs
are also generated in a model of self-resolving inflammation.
The transient increase in LDNs toward the onset of resolution
suggests that they may play a role in this process. Indeed,
we found that the increase in LDNs in this context has func-
tional consequences as the adoptive transfer of LDNs into the
inflamed peritoneum induced changes associated with earlier
onset of resolution (Figure S3). In addition, our findings indicate
that LDNs are generated by TGF-b (Figure 5), a major effector
cytokine in the resolution of inflammation (Henson and Bratton,
2013). These findings suggest that the accumulation of LDNs
may be an integral part of the inflammatory process where neu-
trophils with a reduced inflammatory profile take part in its res-
olution. By analogy, the tumor microenvironment is a site of
chronic inflammation, and we propose that in this scenario
LDNs are generated toward resolution of tumor-associated
inflammation. However, because tumor-associated inflamma-
tion is never resolved, this process is skewed and LDNs
continue to accumulate, leading to an overall protumor neutro-
phil phenotype.
LDNs were previously implicated in several pathological sce-
narios including autoimmune diseases (Denny et al., 2010), HIV570 Cell Reports 10, 562–573, February 3, 2015 ª2015 The Authors(Cloke et al., 2012), severe infection (Morisaki et al., 1992), and
cancer (Brandau et al., 2011). In the context of cancer, LDNs
were usually thought to be G-MDSCs. However, MDSCs are
characterized as immature cells, and, whereas immature neutro-
phils in the LD fraction could be indeed G-MDSCs (Youn et al.,
2008), the presence of mature neutrophils, in patients and in tu-
mor-bearing mice, in this fraction was not previously shown.
With the ability to physically separate pro- and antitumor neutro-
phils, we were able to gain insight into the cellular origins of the
different neutrophil subpopulations and their dynamics with tu-
mor progression. Although HDNs and LDNs may be derived
from a common progenitor, their release into the circulation is
differentially regulated (Figure 4). LDNs rapidly accumulate in
the circulation, whereas HDNs appear in the circulation much
later. These data are compatible with the appearance of imma-
ture neutrophils in the LD fraction and the time needed for
HDNs to complete their maturation in the bone marrow. Impor-
tantly, the release of immature neutrophils to the circulation is
not the result of bone-marrow depletion of HDNs because it
occurs while there are still significant numbers of bone marrow
residing HDNs.
Neutrophil Heterogeneity and Plasticity
Through adoptive transfer experiments, we were able to show
that in tumor-bearing mice mature HDNs can switch to the
low-density fraction. This is accompanied by an increase in
size and the gain of an immunosuppressive protumor function.
Whereas these experiments demonstrate that a switch in neutro-
phil phenotype occurs in vivo, the full extent of this transition is
difficult to evaluate in vivo due to the low degree of neutrophil
retrieval. However, when we followed the transition from HDN
to LDN ex vivo, we found that it occurs spontaneously only in
late-stage tumor-bearing mice (Figure 4). We further demon-
strate that this functional change does not represent degranula-
tion and is driven by TGF-b (Figure 5). Interestingly, we have
previously shown that TGF-b blocks the antitumor function of
neutrophils (Granot et al., 2011) and induces an N2 protumor
phenotype (Fridlender et al., 2009). Finally, in vivo depletion of
TGF-b results in a significant decrease in LDNs providing an indi-
cation for the role TGF-b plays in regulating the LDN/HDN ratio
in vivo. However, although TGF-b is both required and sufficient
for driving the transition of HDNs in tumor-bearing mice to LDNs,
it had no significant effect on HDNs from naive mice suggesting
that further activation of HDNs is required for TGF-b to have an
effect. This activation is most likely a direct consequence of
the significantly different chemokine/cytokine milieu neutrophils
encounter in the context of cancer (Sionov et al., 2014). Taken
together, these findings demonstrate again the major impor-
tance of TGF-b in the innate immune responses to tumor pro-
gression and highlight this signaling pathway as a possible target
for anticancer therapy. This notion is further supported by obser-
vations showing that myeloid cell-specific ablation of TGF-b
signaling enhancesmyeloid cell antitumor properties and inhibits
tumor growth (Novitskiy et al., 2012). Our observations suggest
that, on top of blocking neutrophil cytotoxicity, TGF-b mediates
a shift in the equilibrium between neutrophil subtypes with con-
flicting roles. We further show that not only can HDNs switch to
become LDNs, but also a fraction of the circulating LDNs have
Figure 7. Distinct Circulating Neutrophil
Subtypes in Cancer
Circulating neutrophils, characterized as
Ly6G+CD11b+, may be distinguished according to
their density. Circulating high-density neutrophils
(HDNs) previously described as TENs (Granot
et al., 2011) are N1-like, provide antitumor func-
tions, and are designated NC1. Circulating low-
density neutrophils consist of mature and imma-
ture cells. The immature cells were previously
described as G-MDSCs (Youn et al., 2008) and
provide immunosuppressive functions associated
with protumor contribution. The mature low-den-
sity neutrophils are derived from NC1 but have
reduced neutrophil functions, are less inflamma-
tory, are not cytotoxic, acquire immunosuppres-
sive functions, have an overall N2-like phenotype,
and are designated NC2.the capacity to switch to the HDN fraction, both in vivo and
ex vivo (Figure 3). In light of the immature state of a subset of
LDNs and the mature state of all HDNs, the low- to high-density
transition raises the possibility of neutrophil maturation in the cir-
culation, challenging the current paradigm (Galli et al., 2011) and
requiring further exploration.
Collectively, our data show that circulating neutrophils may be
roughly divided into mature and immature cells. Although imma-
ture neutrophils are commonly referred to as G-MDSCs, there is
clear need for a nomenclature to account for the distinction be-
tween mature HDN (TENs) and our newly described mature
LDNs. Therefore, we propose that the two subtypes of mature
circulating neutrophils (NC) be designated NC1 (N1-like NC) for
mature HDNs and NC2 for mature LDNs (Figure 7).
It is generally accepted that identifying human MDSCs is
complicated by the lack of a specific known marker and due to
the absence of a human homolog of murine GR1 (Solito et al.,
2014). Different markers have been suggested to describe G-
MDSCs, but no specific marker has been agreed upon (Dumitru
et al., 2012; Solito et al., 2014). Our data may suggest a previ-
ously unevaluated way to isolate and further characterize human
G-MDSCs, namely, by their density and appearance. Further
research to explore this possibility is warranted.
Our study provides a perspective of neutrophil function in can-
cer where dynamic changes within multiple neutrophil subtypes
are integrated toward overall pro- or antitumor neutrophil contri-
bution. These observations challenge the current concept of
circulating neutrophils as a fully differentiated homogenous cell
population that has limited plasticity. They also provide a mech-
anistic explanation for the controversy that surrounds neutrophil
function in cancer. It is possible that our findings also open an
avenue for the identification of additional neutrophil subtypes.
Although neutrophils are short lived, their remarkable plasticity
is manifested in acquisition of different, or even opposing,
phenotypes in response to environmental cues. UnderstandingCell Reports 10, 562–573these cues and their consequences on
neutrophil function may serve to enhance
the proportion of favorable neutrophil
subpopulations at the expense of the
harmful subpopulations. This, in turn, may serve as an unex-




Five- to 7-week-old Balb/c, C57/Bl6, and C57/Bl6-CAG-EGFP mice were pur-
chased from the Jackson Laboratory and Harlan (Israel). LSL KrasG12D mice
were kindly provided by Prof. Yuval Dor of the Hebrew University, Jerusalem,
Israel. All experiments involving animals were approved by the HebrewUniver-
sity’s Institutional Animal Care and Use Committee (IACUC).
Cell Lines
4T1 cells were purchased from the ATCC. E0771 cells were kindly provided by
Dr. Ross L. Levine, Memorial Sloan-Kettering Cancer Center. AB12 cells were
kindly provided by Dr. Steven Albelda from the University of Pennsylvania.
AT-3 cells were kindly provided by Dr. Scott Abrams, Roswell Park Cancer
Institute, Buffalo, NY. Cells were transduced with a lentiviral vector (pLVX-
Luc) to stably express firefly luciferase. 4T1, E0771, and AT-3 cells were ortho-
topically injected into the mammary fat pad. AB12 cells were introduced
subcutaneously.
Mutated K-ras Orthotopic Lung Cancer Model
The orthotopic lung cancer model using intratracheal Ad.Cre in transgenic
K-ras mice has been previously described in detail (Wilderman et al., 2005).
Briefly, to activate the conditional oncogene and induce tumors, 100 ml of sa-
line with 33 1010 particles of adenovirus containing Cre recombinase (Ad.Cre)
were administered intranasally to LSL KrasG12D mice. Circulating neutrophils
were evaluated 2 months after instillation of Ad.Cre.
Mouse Neutrophil Purification
Whole blood was collected by cardiac puncture using heparinized (Sigma) sy-
ringe. The blood was diluted with 5 vol of PBS containing 0.5% BSA and sub-
jected to a discontinuous Histopaque (Sigma) gradient (1.077 and 1.119).
HDNs were collected from the 1.077-1.119 interface. LDNs were collected
from the plasma-1.077 interface. Red blood cells (RBCs) were eliminated by
hypotonic lysis. Neutrophil purity and viability were determined visually and
were consistently >98% for HDNs. LDN purity depended on tumor stage
and was up to 82%. For functional assays, where greater neutrophil purity, February 3, 2015 ª2015 The Authors 571
was required, Ly6G+ cells were further purified using the anti-Ly6G MicroBe-
ads kit (Miltenyi) or EasySep kit (STEMCELL Technologies).
Human Neutrophil Purification
Collection of blood from patients was approved by Hadassah Medical Center
institutional review board. Following informed consent, blood samples (10ml)
were collected from healthy volunteers or from lung or breast cancer patients.
Blood samples were transferred to the lab for analysis no more than 15 min af-
ter blood draw. Heparinzed blood (20 U/ml) was mixed with an equal volume of
Dextran 500 (3% in saline) and incubated 30 min at room temperature. The
leukocyte-rich supernatant was layered on top of Histopaque 1077 (Sigma)
and centrifuged. High-density neutrophils were collected in the pellet fraction.
LDNs were collected from the 1077-plasma interface. Neutrophils were resus-
pended in 10 ml 0.2% NaCl for 30 s to remove contaminating erythrocytes.
Isotonicity was restored by the addition of 10 ml 1.6% NaCl. Neutrophils
were than washed three times in Hanks’s balanced salt solution. The percent-
age of neutrophils out of the LD fraction was measured with flow cytometry,
and the percentage of LDNs out of all neutrophil was then calculated.
Statistical Analysis
For studies comparing differences between two groups, we used unpaired
Student’s t tests. For studies comparing more than two groups, we used
ANOVA with appropriate post hoc testing. Differences were considered signif-
icant when p < 0.05. Data are presented as mean ± SEM. Differences were
considered significant when p < 0.05.
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